A consortium of CPI, GlaxoSmithKline, Green Biologics, and Stratophase, The APPLES project developed a cost-effective, multi-parametric sensor system for increasing the efficiency of high-value liquid based production processes. The project set out to maximise yield and minimise waste within high value manufacturing processes.
CPI is working within a consortium of GlaxoSmithKline (GSK) and Green Biologics, led by Stratophase (VC-funded spin-out from the University of Southampton), which is developing a cost-effective, multi-parametric sensor system for increasing the efficiency of high-value liquid based production processes. The £1.2m APPLES (Advanced Process and Production Light Enabled Sensors) project is funded with assistance from the UK government-sponsored Technology Strategy Board.
The project sets out to maximise yield and minimise waste within high value manufacturing processes. This is achieved through a better understanding of real-time processes, thus enabling GSK, Green Biologics and CPI to enhance their ability to develop, and scale up, both existing and novel biofuel and active pharmaceutical ingredient production processes. The consortium is producing and validating a sensor system capable of monitoring multiple parameters in liquids both non-disruptively and in-line throughout the production cycle to provide superior economical benefit and clear environmental dividends.
The APPLES project will result in more efficient processes than are currently available through application of a cheaper and more informative monitoring system. The realisation of such a monitoring system would not be possible without close collaboration between experts in process development and sensing technology, the support from the Technology Strategy Board has been invaluable in the formation of such a strong consortium.Dr Richard Williams
CEO of Stratosphase